尽管选择性兴奋性氨基酸转运蛋白亚型1(EAAT1)抑制剂UCPH-101已成为EAAT研究领域中体外和离体研究的标准药理工具化合物,但它无法穿透血脑屏障,因此不适合用于体内研究。在本研究中,口服(PO)给药(40毫克千克-1大鼠密切相关的类似物UCPH-102的),得到的10.5和6.67μ各自血浆和脑浓度米,1个小时后。设计并合成了三个类似物系列以改善UCPH-102的生物利用度,但在这方面均未显示出实质性的改善。体外的UCPH-102(10μ分析米)在放射性配体结合试验中针对51个中枢神经系统靶标,强烈表明该化合物对EAAT1具有完全选择性。最后,在啮齿动物运动模型中,口服UCPH-102(20 mg kg -1)不会引起急性作用或行为的任何可见变化。
The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
[EN] HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS<br/>[FR] DÉRIVÉS D'HYDANTOÏNE UTILES EN TANT QU'INHIBITEURS DE KV3
申请人:AUTIFONY THERAPEUTICS LTD
公开号:WO2012076877A1
公开(公告)日:2012-06-14
The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.